ISIN.com update: Following approval from regulatory bodies, as well as completion of consultations with employee representatives, Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the successful closing of the transaction to acquire 100% of the Biomnis Group on the 14th of October, 2015.

As communicated on the 22nd of June, the Group intends to offer other prominent groups of laboratory networks in the clinical biology testing market in France the option to co-invest in Biomnis in the future. This planned partnership is in line with Eurofins’ intention to closely collaborate with all the stakeholders in the French medical laboratories sector to support them in fulfilling their objective of contributing to world-class patient care in France.

Generating revenues of over EUR 220m in 2014, Biomnis is one of the largest independent esoteric laboratories in Europe focusing on specialty diagnostic testing, and should provide Eurofins a strong platform on which to deploy the competencies in specialty clinical diagnostic testing that the Group has obtained, and continues to develop, at its recently-acquired laboratories in the US. In return, Biomnis will have access to the full range of Eurofins’ growing esoteric testing portfolio to further develop its leadership in specialty clinical diagnostic testing market in France, and more widely in Europe.

As part of Eurofins’ plans to support Biomnis’ objective to become the leading specialty clinical diagnostics testing provider in Europe, its current leader, Dr. Charles Woler and the entire Biomnis management team will remain with the company. Furthermore, the Biomnis team is pleased to welcome Mr. François Cornu, a seasoned biologist renowned in the French clinical biology market, who will be joining as President of Biomnis specialty laboratory.

For more information about Eurofins, please visit www.eurofins.com

courtesy of business wire.